Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Whitehawk Therapeutics (WHWK) over the last 6 years, with Q3 2025 value amounting to -$177000.0.

  • Whitehawk Therapeutics' Other Operating Expenses changed N/A to -$177000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 939902.91%. This contributed to the annual value of $3.0 million for FY2024, which is 765.4% up from last year.
  • Whitehawk Therapeutics' Other Operating Expenses amounted to -$177000.0 in Q3 2025.
  • In the past 5 years, Whitehawk Therapeutics' Other Operating Expenses ranged from a high of $87.4 million in Q1 2025 and a low of -$177000.0 during Q3 2025
  • For the 5-year period, Whitehawk Therapeutics' Other Operating Expenses averaged around $14.2 million, with its median value being $676500.0 (2023).
  • Per our database at Business Quant, Whitehawk Therapeutics' Other Operating Expenses tumbled by 9920.03% in 2022 and then surged by 31756.76% in 2023.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Other Operating Expenses stood at $74.2 million in 2021, then crashed by 99.7% to $222000.0 in 2022, then soared by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then plummeted by 122.41% to -$177000.0 in 2025.
  • Its Other Operating Expenses stands at -$177000.0 for Q3 2025, versus $87.4 million for Q1 2025 and $790000.0 for Q4 2024.